Loading data for BGLC — first visit, this takes a few seconds.
BioNexus Gene Lab Corp. (BGLC)
NasdaqCM: BGLC
· Real-Time Price · USD
1.54
-0.05 (-3.14%)
At close: Aug 18, 2026, 1:54 PM
BioNexus Gene Lab Corp. (BGLC) Stock Price, Analysis & Data
-3.14% (1D)
| Bid | 1.16 |
| Market Cap | 3.72M |
| Revenue (ttm) | 5.31M |
| Net Income (ttm) | -2.9M |
| Beta | 2.19 |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 0.46 |
| P/S (ttm) | 0.70 |
| Earnings Date | n/a |
| Ask | 2.06 |
| Volume | 5,996 |
| Avg. Volume (20D) | 104,114 |
| Open | 1.62 |
| Previous Close | 1.59 |
| Day's Range | 1.54 - 1.66 |
| 52-Week Range | 1.07 - 6.10 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BGLC
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chem...
Industry Specialty Chemicals
Sector Basic Materials
IPO Date Jan 8, 2021
Employees 19
Stock Exchange NasdaqCM
Ticker Symbol BGLC
Website https://www.bionexusgenelab.com
Financial Performance
In 2025, BioNexus Gene Lab's revenue was 7.42M, a decrease of -21.93% compared to the previous year's 9.51M. Earnings were -2.98M, an increase of 86.73%.
Financial Statements